The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Benefits of targeted therapeutics in Lung Cancer
David Carbone, MD, PhD from Ohio State University, Columbus, OH discusses the benefits of using targeted therapeutics in the treatment of lung cancer. Targeted therapeutics have a much better side effect profile, with superior brain penetration, reducing the risk of brain metastasis. In addition, due to the better side effect profile, these newer generation drugs allow patients to feel more ‘normal’ during their treatment. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
